#BioFigures: 12 Key French Players launch New Immunotechnology Reference Center MI-mabs

21/03/2015 - 2 minutes

WHO?

MI-mAbs (“MI” for Marseille Immunopole and “mAbs” for monoclonal antibody) is a new immunotechnology center headed by Prof. Francois Romagne, located at the heart of the Marseille-Luminy Scientific and Technological Park, and designed to accelerate the development of new immunotherapy antibodies against cancer and inflammatory disease. Prize-Winner of the program “Investments for the Future” 2011 in the “preindustrial demonstrators” category, for an amount of €19, MI-mAbs intends to strengthen France’s position in the field of immunotherapy antibodies. Indeed, MI-mAbs is the key technological tool of Marseille’s Immunopole, a new cluster aiming to turn Marseille metropolis into a world leader in research and development of immune-based therapies.

WHAT?

MI-mAbs announced the signature of the consortium agreement sealing the commitment of its founders: Aix-Marseille Université (AMU) and its private subsidiary Protisvalor, CNRS, Inserm, the Institut Paoli-Calmettes (IPC), three of their research centers (the Centre d’Immunologie de Marseille-Luminy, the Cancer Research Center of Marseille and the Centre for Immunophenomics),

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member